Payment overview · 2025
General Payments
$278.72
11 reported records · 8 companies
Healthcare provider profile · identity verified
Jill A. Bennett, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HUNTINGDON, TN · NPI 1851317051
Verified facts
What the public records show
CMS Open Payments records show Jill A. Bennett, APRN received $278.72 in general payments during 2025 across 11 reported records.
Abbott Laboratories accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.52 | 17.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 16.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.67 | 15.3% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $42.43 | 15.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $38.70 | 13.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.41 | 10.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.15 | 6.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.84 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $233.72 | 10 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.67 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $42.67 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $42.43 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $38.70 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.41 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
125 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
125 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 311 | 61 |
| Gabapentin | Gabapentin | 296 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 285 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 269 | 60 |
| Losartan Potassium | Losartan Potassium | 255 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 55 |
| Potassium Chloride | Potassium Chloride | 207 | 49 |
| Ozempic | Semaglutide | 185 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 179 | 36 |
| Omeprazole | Omeprazole | 175 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 44 |
| Lisinopril | Lisinopril | 159 | 39 |
| Famotidine | Famotidine | 147 | 45 |
| Simvastatin | Simvastatin | 128 | 26 |
| Jardiance | Empagliflozin | 125 | 26 |
| Trazodone Hcl | Trazodone Hcl | 104 | 19 |
| Metformin Hcl | Metformin Hcl | 100 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 24 |
| Tresiba Flextouch U-100 | Insulin Degludec | 99 | 17 |
| Alprazolam | Alprazolam | 98 | 23 |
| Montelukast Sodium | Montelukast Sodium | 98 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 96 | 71 |
| Furosemide | Furosemide | 96 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 90 | 26 |
| Pregabalin | Pregabalin | 85 | 13 |
| Cefdinir | Cefdinir | 83 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 24 |
| Carvedilol | Carvedilol | 80 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 18 |
| Sertraline Hcl | Sertraline Hcl | 79 | 21 |
| Eliquis | Apixaban | 78 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 21 |
| Meloxicam | Meloxicam | 75 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 23 |
| Ezetimibe | Ezetimibe | 71 | 15 |
| Tramadol Hcl | Tramadol Hcl | 64 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | suppressed |
| Celecoxib | Celecoxib | 62 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 12 |
| Telmisartan | Telmisartan | 49 | 12 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 11 |
| Allopurinol | Allopurinol | 43 | 11 |
| Linzess | Linaclotide | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 20 |
| Torsemide | Torsemide | 40 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 30 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Nystatin | Nystatin | 25 | 15 |
| Rybelsus | Semaglutide | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 24 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 20 |
| Tradjenta | Linagliptin | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Enskyce | Desogestrel-Ethinyl Estradiol | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $278.72 · 11 records | Abbott Laboratories | BEYFORTUS, JARDIANCE, NURTEC ODT, REXULTI, VRAYLAR, YUPELRI, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error